Blog
RSS FeedPosted by Michael Wonder on 09 Jun 2016
NICE’s Eylea guideline ‘out of touch with clinical practice’
9 June 2016 - Bayer says it is disappointed that NICE is supporting NHS use of anti-VEGF therapy Eylea to treat ...
Posted by Michael Wonder on 09 Jun 2016
Canada's health technology assessment agency gives positive recommendation for Opdivo to treat non-small cell lung cancer
8 June 2016 - Opdivo is the first immuno-oncology therapy for lung cancer in Canada to use the body’s own immune ...
Posted by Michael Wonder on 09 Jun 2016
Health sector feedback helps make the most of Government funding boost
9 June 2016 - PHARMAC is today announcing funding of six new treatments across important areas of health, including major advancements ...
Posted by Michael Wonder on 08 Jun 2016
CADTH calls for patient input on submissions from Daiichi Sankyo for edoxaban tosylate
8 June 2016 - CADTH has received notice of pending submissions from Daiichi Sankyo for edoxaban tosylate. ...
Posted by Michael Wonder on 08 Jun 2016
The Cancer Drugs Fund
8 June 2016 - Over the past five years thousands of patients in England have been given access to new but ...
Posted by Michael Wonder on 08 Jun 2016
New fund set up to support research into medicines usage in NZ
8 June 2016 - Why do people not take all the medicine prescribed for them? Why are there differences in the ...
Posted by Michael Wonder on 07 Jun 2016
Registration and reimbursement of new cancer medicines in Australia
7 June 2016 - This letter to the Editor of Value in Health Regional Issues for Asia responds to a ...
Posted by Michael Wonder on 06 Jun 2016
Health system cares for big insurers, big pharma
7 June 2016 - Although there are some differences between the major parties on health policy, all sides embrace the concept ...
Posted by Michael Wonder on 06 Jun 2016
Biosimilar Awareness Initiative Reference Group communiqués
6 June 2016 - The communiqués from the meetings of the Biosimilar Awareness Initiative Reference Group are now available. ...
Posted by Michael Wonder on 04 Jun 2016
CADTH issues final recommendation for nivolumab (Opdivo) for use in patients with non-small-cell lung cancer
3 June 2016 - Final recommendation is conditional on cost-effectivness being improved to an acceptable level. ...
Posted by Michael Wonder on 03 Jun 2016
NICE publishes appraisal consultation for crizotinib (Xalkori) for patients with non-small-cell lung cancer
1 June 2016 - NICE has published an appraisal consultation document for crizotinib (Xalkori) for use by patients with non-small-cell ...
Posted by Michael Wonder on 03 Jun 2016
NICE publishes appraisal consultation for pirfenidone (Esbriet) for patients with idiopathic pulmonary fibrosis
3 June 2016 - NICE has published an appraisal consultation document for pirfenidone (Esbriet) for use by patients with idiopathic ...
Posted by Michael Wonder on 02 Jun 2016
Proposal for the supply of influenza vaccine
2 June 2016 - Following a request for proposals for the supply of influenza vaccine, issued on 3 February 2016, PHARMAC ...
Posted by Michael Wonder on 02 Jun 2016
Cobimetinib in advanced melanoma with BRAF V600 mutation: added benefit now considerable
2 June 2016 - New analyses from the commenting procedure showed further advantages of the drug. ...
Posted by Michael Wonder on 02 Jun 2016
Agenda for the 8 June 2016 TC meeting
1 June 2016 - The Transparency Commission will consider the (continued) reimbursement of dexketoprofen with tramadol hydrochloride (Skudexum), empagliflozin (Jardiance), plasma ...